Physician profile
Jaspreet Kaur
NPI 1710498530
$2,274.95
in general payments reported to CMS, 2019-2025
24 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $520 · 2022: $249 · 2023: $407 · 2024: $533 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $406.81 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $330.25 | 2021-2025 | Opzelura, Opzelura, Jakafi |
| Chiesi USA, INC. | $176.02 | 2021-2025 | Cleviprex, Kengreal |
| Botanix Sb INC | $168.74 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $167.22 | 2023-2024 | Vtama |
| Janssen Pharmaceuticals, INC | $166.18 | 2021-2024 | Xarelto |
| Genzyme Corporation | $147.27 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $118.87 | 2021-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $85.20 | 2021-2024 | Aklief |
| Pfizer INC. | $69.22 | 2025 | |
| Janssen Biotech, INC. | $52.55 | 2022-2024 | Tremfya, Rybrevant |
| Leo Pharma INC. | $51.44 | 2025 | Adbry, Anzupgo |
| Almirall LLC | $43.73 | 2021 | |
| Ucb, INC. | $40.77 | 2023-2025 | Cimzia, Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.23 | 2022-2023 | Arazlo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $38.18 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $33.17 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $24.18 | 2023 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $24.09 | 2024 | Sotyktu |
| Abbvie INC. | $23.40 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.37 | 2022 | |
| Lilly USA, LLC | $17.68 | 2023 | Taltz |
| Journey Medical Corporation | $17.62 | 2022 | |
| Organon LLC | $11.76 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.